Page 3 of 3: studies 41 to 44 of 44, newest first. Back to the psilocybin overview
Clinical pharmacist 2017
Psilocybin, a psychoactive component of magic mushrooms, is thought to have therapeutic potential in psychiatric disorders but its mechanism of action within the brain is unclear. In a study, researchers gave two doses of psilocybin to 19 patients with treatment-resistant depression, and studied blood flow within the brain using functional magnetic resonance imaging (MRI) at […]
Current Topics in Behavioral Neurosciences 2017 Juan F López-Giménez, Javier González-Maeso 302 citations
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include naturally occurring chemicals such as mescaline and psilocybin, as well as synthetic compounds, such as lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion, and cognition. The discovery of the hallucinogenic...
Bristol Research 2017 Paul J. May preprint
This is the Molecule of the Month entry for October 1999 about psilocybin and mescaline. It is a pdf archive version of the HTML webpage.
Mental Health Clinician 2017 Jeremy Daniel, Margaret Haberman 78 citations
Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of...